{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:09:22Z","timestamp":1790644162919,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The kidney is one of the organs most frequently affected in immunoglobulin G4-related disease (IgG4-RD). Early identification of IgG4-RD with renal injury by clinical features is a current challenge. There is a paucity of data regarding the clinical features of renal involvement in IgG4-RD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials<\/jats:title>\n                    <jats:p>Patients with the diagnosis of IgG4-RD with and without renal injury were included in the retrospective cohort study. Cox regression analyses were used to investigate the risk factors for disease relapse and to construct the nomogram model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      From December 2014 to February 2022, 54 patients with IgG4-RD were retrospectively enrolled. Renal involvement in IgG4-RD was observed in 55.6% of the patients. The differences of age and lacrimal gland accumulation were statistically significant (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001, and\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.034, respectively). Age was significantly higher in the kidney injury group. Regarding laboratory findings, basophil counts, hemoglobin levels, and serum cholinesterase level were significantly lower in patients with renal involvement (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.033,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.006 and\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.019). Erythrocyte sedimentation rate level was significantly higher in patients with renal involvement (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.017). Seven (23.4%) patients in the kidney injury group relapsed during follow-up with mean recurrence time 9.86\u2009\u00b1\u20097.08\u00a0months. Early diagnosis plays a key role in patient outcomes. Female, elevated erythrocyte sedimentation rate level, and elevated complement component 4 are the risk factors for the disease relapse of IgG4-RD patients. Moreover, an effective nomogram model has been developed to predict disease relapse in patients with IgG4-RD.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10238-025-01612-3","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T06:53:14Z","timestamp":1743144794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of clinical features between patients with and without renal involvement in IgG4-related disease"],"prefix":"10.1007","volume":"25","author":[{"given":"Qixing","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganyuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenke","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangbin","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"1612_CR1","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.autrev.2014.08.013","volume":"13","author":"P Brito-Zer\u00f3n","year":"2014","unstructured":"Brito-Zer\u00f3n P, Ramos-Casals M, Bosch X, Stone JH. The clinical spectrum of IgG4-related disease. Autoimmun Rev. 2014;13:1203\u201310. https:\/\/doi.org\/10.1016\/j.autrev.2014.08.013.","journal-title":"Autoimmun Rev"},{"key":"1612_CR2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000680","volume":"94","author":"D Inoue","year":"2015","unstructured":"Inoue D, Yoshida K, Yoneda N, Ozaki K, Matsubara T, Nagai K, et al. IgG4-related disease: dataset of 235 consecutive patients. Medicine (Baltimore). 2015;94: e680. https:\/\/doi.org\/10.1097\/MD.0000000000000680.","journal-title":"Medicine (Baltimore)"},{"key":"1612_CR3","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1111\/jgh.15809","volume":"37","author":"K Sumimoto","year":"2022","unstructured":"Sumimoto K, Uchida K, Ikeura T, Hirano K, Yamamoto M, Takahashi H, et al. Nationwide epidemiological survey of immunoglobulin G4-related disease with malignancy in Japan. J Gastroenterol Hepatol. 2022;37:1022\u201333. https:\/\/doi.org\/10.1111\/jgh.15809.","journal-title":"J Gastroenterol Hepatol"},{"key":"1612_CR4","doi-asserted-by":"publisher","first-page":"292","DOI":"10.5414\/CN110492","volume":"95","author":"M Mbengue","year":"2021","unstructured":"Mbengue M, Goumri N, Niang A. IgG4-related kidney disease: pathogenesis, diagnosis, and treatment. Clin Nephrol. 2021;95:292\u2013302. https:\/\/doi.org\/10.5414\/CN110492.","journal-title":"Clin Nephrol"},{"key":"1612_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ekir.2018.08.011","volume":"4","author":"RDR Evans","year":"2019","unstructured":"Evans RDR, Cargill T, Goodchild G, Oliveira B, Rodriguez-Justo M, Pepper R, et al. Clinical manifestations and long-term outcomes of IgG4-related kidney and retroperitoneal involvement in a United Kingdom IgG4-related disease cohort. Kidney Int Rep. 2019;4:48\u201358. https:\/\/doi.org\/10.1016\/j.ekir.2018.08.011.","journal-title":"Kidney Int Rep"},{"key":"1612_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1136\/annrheumdis-2019-216561","volume":"79","author":"ZS Wallace","year":"2020","unstructured":"Wallace ZS, Naden RP, Chari S, Choi HK, Della-Torre E, Dicaire J-F, et al. The 2019 American College of Rheumatology\/European League Against Rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis. 2020;79:77\u201387. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216561.","journal-title":"Ann Rheum Dis"},{"key":"1612_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1056\/NEJMra1604481","volume":"385","author":"JR Ingelfinger","year":"2021","unstructured":"Ingelfinger JR. Hematuria in adults. N Engl J Med. 2021;385:153\u201363. https:\/\/doi.org\/10.1056\/NEJMra1604481.","journal-title":"N Engl J Med"},{"key":"1612_CR8","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1148\/rg.2020200043","volume":"40","author":"JW Oh","year":"2020","unstructured":"Oh JW, Rha SE, Choi MH, Oh SN, Youn SY, Choi J-I. Immunoglobulin G4\u2013related disease of the genitourinary system: spectrum of imaging findings and clinical-pathologic features. Radiographics. 2020;40:1265\u201383. https:\/\/doi.org\/10.1148\/rg.2020200043.","journal-title":"Radiographics"},{"key":"1612_CR9","doi-asserted-by":"publisher","first-page":"10262","DOI":"10.1038\/s41598-018-28405-x","volume":"8","author":"M Shirakashi","year":"2018","unstructured":"Shirakashi M, Yoshifuji H, Kodama Y, Chiba T, Yamamoto M, Takahashi H, et al. Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study. Sci Rep. 2018;8:10262. https:\/\/doi.org\/10.1038\/s41598-018-28405-x.","journal-title":"Sci Rep"},{"key":"1612_CR10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/rheumatology\/key227","volume":"58","author":"F Yunyun","year":"2019","unstructured":"Yunyun F, Yu P, Panpan Z, Xia Z, Linyi P, Jiaxin Z, et al. Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial. Rheumatology. 2019;58:52\u201360. https:\/\/doi.org\/10.1093\/rheumatology\/key227.","journal-title":"Rheumatology"},{"key":"1612_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/978-4-431-54228-5_6","volume-title":"IgG4-Relat Dis","author":"H Umehara","year":"2014","unstructured":"Umehara H, Okazaki K. Comprehensive Diagnostic Criteria for IgG4-Related Disease. In: Umehara H, Okazaki K, Stone JH, Kawa S, Kawano M, editors. IgG4-Relat Dis. Tokyo: Springer; 2014. p. 35\u20139."},{"key":"1612_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1681\/ASN.2016020154","volume":"28","author":"A Denic","year":"2017","unstructured":"Denic A, Lieske JC, Chakkera HA, Poggio ED, Alexander MP, Singh P, et al. The substantial loss of nephrons in healthy human kidneys with aging. J Am Soc Nephrol. 2017;28:313\u201320. https:\/\/doi.org\/10.1681\/ASN.2016020154.","journal-title":"J Am Soc Nephrol"},{"key":"1612_CR13","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1056\/NEJMoa1614329","volume":"376","author":"A Denic","year":"2017","unstructured":"Denic A, Mathew J, Lerman LO, Lieske JC, Larson JJ, Alexander MP, et al. Single-nephron glomerular filtration rate in healthy adults. N Engl J Med. 2017;376:2349\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1614329.","journal-title":"N Engl J Med"},{"key":"1612_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.coi.2010.01.012","volume":"22","author":"CL Sokol","year":"2010","unstructured":"Sokol CL, Medzhitov R. Role of basophils in the initiation of Th2 responses. Curr Opin Immunol. 2010;22:73\u20137. https:\/\/doi.org\/10.1016\/j.coi.2010.01.012.","journal-title":"Curr Opin Immunol"},{"key":"1612_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00535-012-0626-8","volume":"48","author":"T Watanabe","year":"2013","unstructured":"Watanabe T, Yamashita K, Sakurai T, Kudo M, Shiokawa M, Uza N, et al. Toll-like receptor activation in basophils contributes to the development of IgG4-related disease. J Gastroenterol. 2013;48:247\u201353. https:\/\/doi.org\/10.1007\/s00535-012-0626-8.","journal-title":"J Gastroenterol"},{"key":"1612_CR16","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.immuni.2016.02.015","volume":"44","author":"TA Wynn","year":"2016","unstructured":"Wynn TA, Vannella KM. Macrophages in tissue repair, regeneration, and fibrosis. Immunity. 2016;44:450\u201362. https:\/\/doi.org\/10.1016\/j.immuni.2016.02.015.","journal-title":"Immunity"},{"key":"1612_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/mi.2009.137","volume":"3","author":"CL Sokol","year":"2010","unstructured":"Sokol CL, Medzhitov R. Emerging functions of basophils in protective and allergic immune responses. Mucosal Immunol. 2010;3:129\u201337. https:\/\/doi.org\/10.1038\/mi.2009.137.","journal-title":"Mucosal Immunol"},{"key":"1612_CR18","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/s41591-018-0194-4","volume":"24","author":"C Qiu","year":"2018","unstructured":"Qiu C, Huang S, Park J, Park Y, Ko Y-A, Seasock MJ, et al. Renal compartment\u2013specific genetic variation analyses identify new pathways in chronic kidney disease. Nat Med. 2018;24:1721\u201331. https:\/\/doi.org\/10.1038\/s41591-018-0194-4.","journal-title":"Nat Med"},{"key":"1612_CR19","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1172\/JCI81166","volume":"125","author":"J-H Baek","year":"2015","unstructured":"Baek J-H, Zeng R, Weinmann-Menke J, Valerius MT, Wada Y, Ajay AK, et al. IL-34 mediates acute kidney injury and worsens subsequent chronic kidney disease. J Clin Invest. 2015;125:3198\u2013214. https:\/\/doi.org\/10.1172\/JCI81166.","journal-title":"J Clin Invest"},{"key":"1612_CR20","doi-asserted-by":"publisher","first-page":"28715","DOI":"10.1038\/srep28715","volume":"6","author":"H Liang","year":"2016","unstructured":"Liang H, Ma Z, Peng H, He L, Hu Z, Wang Y. CXCL16 deficiency attenuates renal injury and fibrosis in salt-sensitive hypertension. Sci Rep. 2016;6:28715. https:\/\/doi.org\/10.1038\/srep28715.","journal-title":"Sci Rep"},{"key":"1612_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejphar.2017.06.031","volume":"812","author":"H Liang","year":"2017","unstructured":"Liang H, Xu F, Wen X-J, Liu H-Z, Wang H-B, Zhong J-Y, et al. Interleukin-33 signaling contributes to renal fibrosis following ischemia reperfusion. Eur J Pharmacol. 2017;812:18\u201327. https:\/\/doi.org\/10.1016\/j.ejphar.2017.06.031.","journal-title":"Eur J Pharmacol"},{"key":"1612_CR22","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41590-022-01200-7","volume":"23","author":"T Doke","year":"2022","unstructured":"Doke T, Abedini A, Aldridge DL, Yang Y-W, Park J, Hernandez CM, et al. Single-cell analysis identifies the interaction of altered renal tubules with basophils orchestrating kidney fibrosis. Nat Immunol. 2022;23:947\u201359. https:\/\/doi.org\/10.1038\/s41590-022-01200-7.","journal-title":"Nat Immunol"},{"key":"1612_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3389\/fmed.2020.00047","volume":"7","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhu X, Huang X, Wei X, Zhao D, Jiang L, et al. Advances in understanding the effects of erythropoietin on renal fibrosis. Front Med. 2020;7:47. https:\/\/doi.org\/10.3389\/fmed.2020.00047.","journal-title":"Front Med"},{"key":"1612_CR24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12882-021-02411-0","volume":"22","author":"Y Iwata","year":"2021","unstructured":"Iwata Y, Sakai N, Nakajima Y, Oshima M, Nakagawa-Yoneda S, Ogura H, et al. Anti-fibrotic potential of erythropoietin signaling on bone marrow derived fibrotic cell. BMC Nephrol. 2021;22:203. https:\/\/doi.org\/10.1186\/s12882-021-02411-0.","journal-title":"BMC Nephrol"},{"key":"1612_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111558","volume":"139","author":"I Silva","year":"2021","unstructured":"Silva I, Al\u00edpio C, Pinto R, Mateus V. Potential anti-inflammatory effect of erythropoietin in non-clinical studies in vivo: a systematic review. Biomed Pharmacother. 2021;139: 111558. https:\/\/doi.org\/10.1016\/j.biopha.2021.111558.","journal-title":"Biomed Pharmacother"},{"key":"1612_CR26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12974-017-0976-5","volume":"14","author":"M Moransard","year":"2017","unstructured":"Moransard M, Bednar M, Frei K, Gassmann M, Ogunshola OO. Erythropoietin reduces experimental autoimmune encephalomyelitis severity via neuroprotective mechanisms. J Neuroinflammation. 2017;14:202. https:\/\/doi.org\/10.1186\/s12974-017-0976-5.","journal-title":"J Neuroinflammation"},{"key":"1612_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/82_2016_41","volume-title":"IgG4-Relat Dis","author":"K Uchida","year":"2016","unstructured":"Uchida K, Okazaki K. Roles of Regulatory T and B Cells in IgG4-Related Disease. In: Okazaki K, editor. IgG4-Relat Dis, vol. 401. Cham: Springer; 2016. p. 93\u2013114."},{"key":"1612_CR28","doi-asserted-by":"publisher","first-page":"rkaa031","DOI":"10.1093\/rap\/rkaa031","volume":"4","author":"K Hamada-Ode","year":"2020","unstructured":"Hamada-Ode K, Yoshida M, Terada Y, Taniguchi Y. Is serum cholinesterase level a predictor of the extent of organ involvement in immunoglobulin G4-related disease? Rheumatol Adv Pract. 2020;4:rkaa031. https:\/\/doi.org\/10.1093\/rap\/rkaa031.","journal-title":"Rheumatol Adv Pract"},{"key":"1612_CR29","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.cca.2006.11.005","volume":"378","author":"I Manoharan","year":"2007","unstructured":"Manoharan I, Boopathy R, Darvesh S, Lockridge O. A medical health report on individuals with silent butyrylcholinesterase in the Vysya community of India. Clin Chim Acta. 2007;378:128\u201335. https:\/\/doi.org\/10.1016\/j.cca.2006.11.005.","journal-title":"Clin Chim Acta"},{"key":"1612_CR30","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1002\/art.39132","volume":"67","author":"A Khosroshahi","year":"2015","unstructured":"Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers MN, et al. International consensus guidance statement on the management and treatment of IgG4-related disease: international consensus statement on IgG4-RD management. Arthritis Rheumatol. 2015;67:1688\u201399. https:\/\/doi.org\/10.1002\/art.39132.","journal-title":"Arthritis Rheumatol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01612-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01612-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01612-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:50:30Z","timestamp":1764917430000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01612-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1612"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01612-3","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"23 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The studies involving human participants were reviewed and approved by the Ethical Committee of our Hospital. The patients\/participants provided their written informed consent to participate in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Clinical trial number not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"95"}}